Characterization of Sitagliptin Use in Patients with Type 2 Diabetes and Chronic Kidney Disease by Cross-Sectional Analysis of a Medical Insurance Claims Database

INTRODUCTION: Chronic kidney disease (CKD) is common in patients with type 2 diabetes (T2DM) and makes them particularly susceptible to safety/tolerability issues related to many classes of oral antihyperglycemic agents (OAHA). Dipeptidyl peptidase-4 inhibitors (DPP-4is) like sitagliptin are general...

Descripción completa

Detalles Bibliográficos
Autores principales: Brodovicz, Kimberly G., Chen, Yong, Liu, Zhiwen, Ritchey, Mary E., Liao, Jane, Engel, Samuel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674473/
https://www.ncbi.nlm.nih.gov/pubmed/26438107
http://dx.doi.org/10.1007/s13300-015-0133-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674473/
https://www.ncbi.nlm.nih.gov/pubmed/26438107
http://dx.doi.org/10.1007/s13300-015-0133-z

Ejemplares similares